Business
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain. Held productive interaction with U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study. Participated in 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, showcasing progression of Sangamo’s neurology pipeline
About this update from Sangamo Therapeutics, Inc.
[{"type":"image","alt":"Sangamo Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sangamo Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/dc00e2ffd577d3c5ddd72548c6e29e7f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yqjv.8GrNgvCZN5FGKWCtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/dc00e2ffd577d3c5ddd72548c6e29e7f","width":300,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/yqjv.8GrNgvCZN5FGKWCtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/dc00e2ffd577d3c5ddd72548c6e29e7f","width":300,"height":74}},"lazy":false},{"type":"text","content":"Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress.","length":138,"tagName":"p"},{"type":"text","content":"Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.","length":91,"tagName":"p"},{"type":"text","content":"Held productive interaction with U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study.","length":128,"tagName":"p"},{"type":"text","content":"Participated in 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, showcasing progression of Sangamo’s neurology pipeline and advances in modular integrase technology.","length":189,"tagName":"p"},{"type":"text","content":"RICHMOND, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2026 financial results.","length":219,"tagName":"p"},{"type":"text","content":"“During the first quarter, we advanced our rolling BLA submission for ST-920 and continued to progress our differentiated neurology pipeline,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We remain focused on executing against our regulatory and clinical priorities while pursuing opportunities to secure additional funding and support the long-term potential of our pipeline.”","length":401,"tagName":"p"},{"type":"text","content":"Recent Business Highlights","length":26,"tagName":"p"},{"type":"text","content":"Corporate Updates","length":17...